Open AccessIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Author(s) -
Douglas B. Johnson,
Ryan J. Sullivan,
Patrick A. Ott,
Matteo S. Carlino,
Nikhil I. Khushalani,
Fei Ye,
Alexander Guminski,
Igor Puzanov,
Donald P. Lawrence,
Elizabeth I. Buchbinder,
Tejaswi Mudigonda,
Kristen Spencer,
Carolin Bender,
Jenny Lee,
Howard L. Kaufman,
Alexander M. Menzies,
Jessica C. Hassel,
Janice M. Mehnert,
Jeffrey A. Sosman,
Georgina V. Long,
Joseph I. Clark
Publication year - 2015
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.4368
Subject(s) - medicine , ipilimumab , infliximab , psoriasis , hydroxychloroquine , melanoma , adverse effect , prednisone , immunosuppression , rheumatoid arthritis , immunology , cancer , immunotherapy , disease , covid-19 , infectious disease (medical specialty) , cancer research
Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom